Distinct effects of cocaine and cocaine plus cannabis on neurocognitive functioning and abstinence: A six-month follow-up study

Imagem de Miniatura
Arquivos
art_OLIVEIRA JUNIOR_Distinct_effects_of_cocaine_and_cocaine_plus_cannabis_2019.PDF (577.39 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
SANTOS, Bernardo dos
Citação
DRUG AND ALCOHOL DEPENDENCE, v.205, article ID UNSP 107642, 8p, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background and Aims: Cannabis use is frequent among individuals with cocaine use disorder. Despite recent non-controlled studies advocating a therapeutic role of smoked cannabis, there is a paucity of evidence-based data on potential therapeutic and cognitive side-effects of this association. Methods: We examined 63 cocaine-addicted subjects who used cannabis more than 50 times in lifetime (COC + CAN), 24 cocaine-addicted patients who use cannabis less than 50 times (COC), and 36 controls (CON). Participants were evaluated with an extensive battery of neurocognitive tests after two weeks of supervised detoxification in an inpatient treatment program. Patients were followed up in one, three, and six months after discharge. Results: Both groups of patients performed worse than CON on working memory, processing speed, inhibitory control, mental flexibility, and decision making. COC + CAN performed worse than COC on speed processing, inhibitory control and sustained attention, while COC performed worse than COC + CAN on mental flexibility. Concomitant cannabis use did not decrease relapses to cocaine use after one, three and six months. Among COC + CAN, earlier cocaine and cannabis use, and impaired executive functioning were predictive of relapse on cocaine after six months. Conclusion: Our results did not support the recommendation of smoked cannabis as a safe therapeutic approach for cocaine-addicted patients due to significant negative cognitive side-effects and absence of efficacy. Further studies investigating frontal brain morphology, neuromaturation, and prescription of the non-psychoactive constituent of cannabis sativa cannabidiol among cocaine-addicted patients who use cannabis are warranted.
Palavras-chave
Cocaine, Cannabis, Polydrug, Cognition, Executive functions
URI
https://observatorio.fm.usp.br/handle/OPI/34522
Referências
  1. American Psychiatric Association, 2000, DIAGN STAT MAN MENT
  2. Andrade T, 2011, DRUG-EDUC PREV POLIC, V18, P382, DOI 10.3109/09687637.2010.506898
  3. ANDREASSON S, 1990, SCAND J SOC MED, V18, P9
  4. Barcelo F, 1997, NEUROPSYCHOLOGIA, V35, P399, DOI 10.1016/S0028-3932(96)00096-6
  5. BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3
  6. BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
  7. BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
  8. Bloomfield MAP, 2019, PHARMACOL THERAPEUT, V195, P132, DOI 10.1016/j.pharmthera.2018.10.006
  9. Bloomfield MAP, 2016, NATURE, V539, P369, DOI 10.1038/nature20153
  10. Bolla KI, 2008, SLEEP, V31, P901, DOI 10.1093/sleep/31.6.901
  11. Broyd SJ, 2016, BIOL PSYCHIAT, V79, P557, DOI 10.1016/j.biopsych.2015.12.002
  12. Cruz MS, 2013, INT J DRUG POLICY, V24, P432, DOI 10.1016/j.drugpo.2013.03.012
  13. Cunha Paulo J, 2004, Rev. Bras. Psiquiatr., V26, P103, DOI 10.1590/S1516-44462004000200007
  14. Deschenau A, 2016, PRESSE MED, V45, P1102, DOI 10.1016/j.lpm.2016.10.010
  15. Di Sclafani V, 2002, DRUG ALCOHOL DEPEN, V66, P161, DOI 10.1016/S0376-8716(01)00197-1
  16. Dreher M, 2002, J CANNABIS THERAPEUT, V2, P121
  17. Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621
  18. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, EUR DRUG REP 2017 TR
  19. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2009, POL US PATT RESP
  20. Fergusson DM, 2015, SOC PSYCH PSYCH EPID, V50, P1317, DOI 10.1007/s00127-015-1070-x
  21. Filbey FM, 2015, DEV COGN NEUROS-NETH, V16, P16, DOI 10.1016/j.dcn.2015.10.001
  22. Fillmore MT, 2002, DRUG ALCOHOL DEPEN, V66, P265, DOI 10.1016/S0376-8716(01)00206-X
  23. Fischer B, 2017, AM J PUBLIC HEALTH, V107, pE1, DOI [10.2105/AJPH.2017.303818, 10.2105/ajph.2017.303818]
  24. Fischer B, 2015, INT J DRUG POLICY, V26, P1177, DOI 10.1016/j.drugpo.2015.09.005
  25. Fontes MA, 2011, BRIT J PSYCHIAT, V198, P442, DOI 10.1192/bjp.bp.110.077479
  26. Ford JD, 2009, DRUG ALCOHOL DEPEN, V99, P193, DOI 10.1016/j.drugalcdep.2008.07.004
  27. Ganzer F, 2016, NEUROPSYCHOL REV, V26, P186, DOI 10.1007/s11065-016-9316-2
  28. Giasson-Gariepy K, 2017, ADDICT BEHAV, V73, P4, DOI 10.1016/j.addbeh.2017.03.025
  29. Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012
  30. Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
  31. Goncalves JR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2063-0
  32. Gonzalez-Cuevas G, 2018, NEUROPSYCHOPHARMACOL, V43, P2036, DOI 10.1038/s41386-018-0050-8
  33. Gorey C, 2019, EUR ARCH PSY CLIN N, V269, P37, DOI 10.1007/s00406-019-00981-7
  34. Gruber SA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.201E00355
  35. Han BH, 2019, DRUG ALCOHOL DEPEN, V198, P121, DOI 10.1016/j.drugalcdep.2019.01.042
  36. Hoff AL, 1996, PSYCHIAT RES, V60, P167, DOI 10.1016/0165-1781(96)02758-8
  37. Hsieh PC, 2010, J PSYCHIATR NEUROSCI, V35, P90, DOI 10.1503/jpn.090007
  38. Cunha PJ, 2010, ADDICT BEHAV, V35, P875, DOI 10.1016/j.addbeh.2010.05.005
  39. Jovanovski D, 2005, J CLIN EXP NEUROPSYC, V27, P189, DOI 10.1080/13803390490515694
  40. Kerridge BT, 2019, ADDICT BEHAV, V90, P250, DOI 10.1016/j.addbeh.2018.11.005
  41. Kessler F, 2012, REV BRAS PSIQUIATR, V34, P24, DOI 10.1590/S1516-44462012000100006
  42. Labigalini E, 1999, J PSYCHOACTIVE DRUGS, V31, P451, DOI 10.1080/02791072.1999.10471776
  43. Lac A, 2018, PREV SCI, V19, P117, DOI 10.1007/s11121-017-0811-3
  44. Lezak M. D., 2004, NEUROPSYCHOLOGICAL A
  45. Lim DR, 2019, DRUG ALCOHOL DEPEN, V197, P255, DOI 10.1016/j.drugalcdep.2019.01.013
  46. Lopes BM, 2017, ADDICT BEHAV, V73, P41, DOI 10.1016/j.addbeh.2017.04.013
  47. Lopes-Rosa R, 2017, J ADDICT DIS, V36, P136, DOI 10.1080/10550887.2017.1295670
  48. McCance-Katz EF, 1999, AM J ADDICTION, V8, P300
  49. McCann BS, 2000, J NEUROPSYCH CLIN N, V12, P240, DOI 10.1176/appi.neuropsych.12.2.240
  50. Nagahama Y, 2005, J NEUROL NEUROSUR PS, V76, P169, DOI 10.1136/jnnp.2004.039818
  51. Oliveira HP, 2018, PSYCHOL ADDICT BEHAV, V32, P812, DOI 10.1037/adb0000410
  52. Osborne AL, 2017, NEUROSCI BIOBEHAV R, V72, P310, DOI 10.1016/j.neubiorev.2016.11.012
  53. Price JS, 2015, PSYCHOPHARMACOLOGY, V232, P2939, DOI 10.1007/s00213-015-3931-0
  54. Prud'homme M, 2015, SUBST ABUS-RES TREAT, V9, P33, DOI 10.4137/SART.S25081
  55. Shoptaw S, 2003, J CLIN PSYCHIAT, V64, P1440, DOI 10.4088/JCP.v64n1207
  56. Socias ME, 2017, ADDICT BEHAV, V72, P138, DOI 10.1016/j.addbeh.2017.04.006
  57. Spielberger CD, 1970, MANUAL STATE TRAIT A
  58. Spronk DB, 2013, NEUROSCI BIOBEHAV R, V37, P1838, DOI 10.1016/j.neubiorev.2013.07.003
  59. Thames AD, 2014, ADDICT BEHAV, V39, P994, DOI 10.1016/j.addbeh.2014.01.019
  60. Tomasi D, 2007, BRAIN RES, V1171, P83, DOI 10.1016/j.brainres.2007.06.102
  61. United Nations Office on Drugs and Crime (UNODC), 2018, WORLD DRUG REP 2018
  62. Vadhan NP, 2014, EXP CLIN PSYCHOPHARM, V22, P65, DOI 10.1037/a0034506
  63. Verdejo-Garcia A, 2018, PHARMACOL BIOCHEM BE, V164, P99, DOI 10.1016/j.pbb.2017.02.003
  64. Viola TW, 2015, EUR ADDICT RES, V21, P273, DOI 10.1159/000430436
  65. Viola TW, 2014, DRUG ALCOHOL DEPEN, V144, P153, DOI 10.1016/j.drugalcdep.2014.09.003
  66. Volkow ND, 2018, AM J PSYCHIAT, V175, P729, DOI 10.1176/appi.ajp.2018.17101174
  67. Wall MB, 2019, J PSYCHOPHARMACOL, V33, P822, DOI 10.1177/0269881119841568
  68. Wechsler D., 1999, WECHSLER ABBREVIATED
  69. Whiting PF, 2015, JAMA-J AM MED ASSOC, V313, P2456, DOI 10.1001/jama.2015.6358
  70. Woicik PA, 2011, NEUROPSYCHOLOGIA, V49, P1660, DOI 10.1016/j.neuropsychologia.2011.02.037
  71. Woicik PA, 2009, NEUROPSYCHOPHARMACOL, V34, P1112, DOI 10.1038/npp.2008.60
  72. Wong SS, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1818
  73. Yucel M, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.201
  74. Zammit S, 2002, BRIT MED J, V325, P1199, DOI 10.1136/bmj.325.7374.1199

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21
Artigos e Materiais de Revistas Científicas - ODS/03